Share on StockTwits

Idera Pharmaceuticals (NASDAQ:IDRA) Director James A. Geraghty purchased 10,000 shares of the stock in a transaction dated Tuesday, May 27th. The stock was purchased at an average price of $2.65 per share, for a total transaction of $26,500.00. Following the acquisition, the director now directly owns 412,649 shares of the company’s stock, valued at approximately $1,093,520. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Idera Pharmaceuticals (NASDAQ:IDRA) opened at 2.90 on Friday. Idera Pharmaceuticals has a 52-week low of $0.62 and a 52-week high of $6.87. The stock’s 50-day moving average is $2.82 and its 200-day moving average is $3.81. The company’s market cap is $239.1 million.

Idera Pharmaceuticals (NASDAQ:IDRA) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.04. During the same quarter in the previous year, the company posted ($0.15) earnings per share. On average, analysts predict that Idera Pharmaceuticals will post $-0.40 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at TheStreet downgraded shares of Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 28th. Separately, analysts at Zacks downgraded shares of Idera Pharmaceuticals to a “neutral” rating in a research note on Thursday, March 6th. They now have a $6.10 price target on the stock. Finally, analysts at Cowen and Company initiated coverage on shares of Idera Pharmaceuticals in a research note on Monday, March 3rd. They set an “outperform” rating on the stock.

Idera Pharmaceuticals, Inc is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (NASDAQ:IDRA) – and ribonucleic acid (RNA) – based drug candidates.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.